期刊文献+

MSCT三期增强扫描联合5种血清肿瘤标志物检测在肺癌诊断及临床病理分型中的应用价值 被引量:17

Application Value of MSCT Three-Phase Enhanced Scan Combined with the Detection of Five Serum Tumor Markers in the Diagnosis of Lung Cancer and Clinical Pathological Typing
下载PDF
导出
摘要 目的分析多层螺旋CT(MSCT)三期增强扫描联合5种血清肿瘤标志物检测在肺癌诊断及临床病理分型中的应用价值。方法回顾性分析2018年6月至2019年12月于我院就诊治疗的94例肺癌患者的临床及影像学资料,另选取60例健康体检者,总结不同检查方式对肺癌诊断的准确率以及相关影像学表现,并比较不同人群相关指标水平。结果肺癌患者CA153、CA125、NSE、.CEA和CYFRA21-1水平均显著高于健康体检者(P<005);MSCT检查联合CA153、CA125、NSE、CEA和CYFRA21-1检测对肺癌的诊断符合率.均显著高于MSCT及5种肿瘤标志物单项检查者(P<005)。结论CA153、CA125、NSE、CEA和CYFRA21-1水平在肺癌患者中显著上升,而MSCT增强扫描检查可清晰显出病灶大小、形态及位置,二者联合对肺癌的诊断价值更高,更值得临床推广使用。 Objective To analyze the application value of multi-slice spiral CT(MsCT) three-phase enhanced scan combined with the detection of five serum tumor markers in the diagnosis of lung cancer and clinical pathological typing. Methods The clinical and imaging data of 94 patients with lung cancer treated in our hospital from June 2018 to December 2019 were retrospectively analyzed. Another 60 healthy medical examiners were selected, and the accuracy of different examinations in the diagnosis of lung cancer and related imaging performance were summarized, and the relevant indicator levels in different people were compared. Results The levels of CA153, CA125, Ns E, CEA, and CYFRA21-1 in patients with lung cancer were significantly higher than those in healthy subjects(P<0.05). The diagnostic accuracy of Ms CT combined with CA153, CA125, Ns E, CEA and CYFRA21-1 tests for lung cancer were significantly higher than those of Ms CT and 5 tumor markers alone(P<0.05). Conclusion The levels of CA153, CA125, Ns E, CEA and CYFRA21-1 significantly increased in patients with lung cancer, and Ms CT enhanced scans can clearly show the size, shape and location of the lesions. The combination of them has higher diagnostic value for lung cancer and it is more worthy of clinical promotion.
作者 曹栋栋 吕伟 王宪章 孙艳 CAO Dong-dong;LYU Wei;WANG Xian-zhang;SUN Yan(Department of Imaging,Xinyi City People's Hospital,Jiangsu Province,Xuzhou 221400,Jiangsu Province,China)
出处 《中国CT和MRI杂志》 2022年第7期64-66,共3页 Chinese Journal of CT and MRI
关键词 多层螺旋CT 血清肿瘤标志物 肺癌 影像学特征 诊断价值 Multi-slice Spiral CT Serum Tumor Markers Lung Cancer Imaging Characteristics Diagnostic Value
  • 相关文献

参考文献13

二级参考文献134

  • 1Mursalin M.Anis,Mir-Muhammad Razavi,Xiao Xiao,Ahmed M.S.Soliman.Association of gastroesophageal reflux disease and laryngeal cancer[J].World Journal of Otorhinolaryngology-Head and Neck Surgery,2018,4(4):278-281. 被引量:5
  • 2崔社怀,金榕兵,曹国强,洪新.FDG-PET对非小细胞肺癌分期的意义[J].第三军医大学学报,2005,27(15):1576-1578. 被引量:3
  • 3黎海涛,王健,陈伟,黎川,厉红民,陈霖,张永克,李中会.^(18)F-FDG PET/CT显像在恶性肿瘤临床诊断中的应用[J].第三军医大学学报,2006,28(7):718-720. 被引量:5
  • 4刘晓东,吴琦,梁春宝.抗痨凝胶介入治疗耐多药肺结核空洞的临床研究[J].临床肺科杂志,2007,12(6):558-559. 被引量:6
  • 5Socinski M A, Novello S, Brahmer J R, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer[J]. J Clin Oncol, 2008, 26(4): 650-656. 被引量:1
  • 6Gatzemeier U, Blumenschein G, Fosell F, et al. Phase Ⅱ trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma (abstract). J Clin Oncol 2006; 24:364s. (Abslract available online at www.asco.org/portal/site/ASCO/menuitem.34 d60f5624ba07fd506fe310ee37a01 d/?vgnextoid=76f8201 eb6 la7010VgnVCM100000ed730adlRCRD, accessed on June 7, 2006). 被引量:1
  • 7Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage lIB-IV non-small cell lung cancer (NSCLC): Interim analysis results from the phase Ⅲ, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, And Paclitaxel Efficacy in NSCLC) trial[J]. J Thorac Oncol, 2008, 3: 687-673. 被引量:1
  • 8Schiller J H, Larson, T, Ou S I, et al. Efficacy and safety of axitinlb (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase Ⅱ trial. (Abstract). J Clin Oncol 2007; 25:386s. (Abstract available online at:www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01 d/?vg nextoid=76f8201 eb61 a7010VgnVCM 100000ed730ad 1RCRD, accessed on June 6, 2007). 被引量:1
  • 9Lilenbaum R, Socinski M A, Altorki N K, et al. Randomized phase Ⅱ trial of docetaxel/irinotecan and gemcitabine/ irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer[J]. J Clin Oncol, 2006, 24(30): 4825-4835. 被引量:1
  • 10Edelman M J, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib +chemolherapy-Cancer and Leukemia Group B Trial 30203[J]. J Clin Oncol, 2008, 26(6): 848-855. 被引量:1

共引文献243

同被引文献214

引证文献17

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部